<!DOCTYPE html><html><head><title>Pharmacologic management of newly detected atrial fibrillation.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Guideline Title
</h3>
<div class='FieldValue'>
<div class="content_title">Pharmacologic management of newly detected atrial fibrillation.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Bibliographic Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>American Academy of Family Physicians. Updated clinical practice guideline: pharmacologic management of newly detected atrial fibrillation. Leawood (KS): American Academy of Family Physicians; 2017 Apr. 19 p.  [33 references]</td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Snow V, Weiss KB, LeFevre M, McNamara R, Bass E, Green LA, Michl K, Owens DK, Susman J, Allen DI, Mottur-Pilson C. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2003 Dec 16;139(12):1009-17. [57 references] </p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>NEATS Assessment
</h2>
<div class='field field_picklist-one'>
<h3>
Disclosure of Guideline Funding Source
</h3>
<div class='FieldValue'>
Yes
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Disclosure and Management of Financial Conflict of Interests
</h3>
<div class='FieldValue'>
5
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Guideline Development Group Composition: Multidisciplinary Group
</h3>
<div class='FieldValue'>
Unknown
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Guideline Development Group Composition: Methodologist Involvement
</h3>
<div class='FieldValue'>
Yes
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Guideline Development Group Composition: Patient and Public Perspectives
</h3>
<div class='FieldValue'>
4
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Use of a Systematic Review of Evidence: Search Strategy
</h3>
<div class='FieldValue'>
5
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Use of a Systematic Review of Evidence: Study Selection
</h3>
<div class='FieldValue'>
5
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Use of a Systematic Review of Evidence: Synthesis of Evidence
</h3>
<div class='FieldValue'>
5
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Evidence Foundations for and Rating Strength of Recommendations: Grading the Quality or Strength of Evidence
</h3>
<div class='FieldValue'>
5
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Evidence Foundations for and Rating Strength of Recommendations: Benefits and Harms of Recommendations
</h3>
<div class='FieldValue'>
5
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Evidence Foundations for and Rating Strength of Recommendations: Evidence Summary Supporting Recommendations
</h3>
<div class='FieldValue'>
4
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Evidence Foundations for and Rating Strength of Recommendations: Rating the Strength of Recommendations
</h3>
<div class='FieldValue'>
5
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Specific and Unambiguous Articulation of Recommendations
</h3>
<div class='FieldValue'>
5
</div>

</div>
<div class='field field_picklist-one'>
<h3>
External Review
</h3>
<div class='FieldValue'>
3
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Updating
</h3>
<div class='FieldValue'>
5
</div>

</div>

</div>
<div class='section'>
<h2>Recommendations
</h2>
<div class='field field_text'>
<h3>
Major Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The quality of evidence (<strong>High, Moderate, Low, Very Low</strong>) and grades of recommendations (<strong>Strong, Weak, Good Practice Point</strong>) are defined at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Recommendation 1</span></strong> </p>
<p>The American Academy of Family Physicians (AAFP) strongly recommends rate control in preference to rhythm control for the majority of patients who have atrial fibrillation (<strong>strong recommendation, moderate-quality evidence</strong>). Preferred options for rate-control therapy include non-dihydropyridine calcium channel blockers and beta blockers. Rhythm control may be considered for certain patients based on patient symptoms, exercise tolerance, and patient preferences (<strong>weak recommendation, low-quality evidence</strong>). </p>
<p><strong><span style="text-decoration: underline;">Recommendation 2</span></strong> </p>
<p>The AAFP recommends lenient rate control (&lt;110 beats per minute resting) over strict rate control (&lt;80 beats per minute resting) for patients who have atrial fibrillation (<strong>weak recommendation, low-quality evidence</strong>). </p>
<p><strong><span style="text-decoration: underline;">Recommendation 3</span></strong> </p>
<p>The AAFP recommends that clinicians discuss the risk of stroke and bleeding with all patients considering anticoagulation (<strong>good practice point</strong>). Clinicians should consider using the continuous CHADS<sub>2</sub> (Congestive heart failure, Hypertension, Age 75+, Diabetes mellitus, prior Stroke, transient ischemic attack or thromboembolic event) or continuous CHA<sub>2</sub>DS<sub>2</sub>-VASc (Congestive heart failure, Hypertension, Age 75+, Diabetes mellitus, prior Stroke, transient ischemic attack or thromboembolic event, Vascular disease, Age 65-74, Sex category) for prediction of risk of stroke (<strong>weak recommendation, low-quality evidence</strong>) and HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly [&gt;65 years], Drugs/alcohol concomitantly) for prediction of risk for bleeding (<strong>weak recommendation, low-quality evidence</strong>) in patients who have atrial fibrillation. </p>
<p><strong><span style="text-decoration: underline;">Recommendation 4</span></strong></p>
<p>The AAFP strongly recommends that patients who have atrial fibrillation receive chronic anticoagulation unless they are at low risk of stroke (CHADS<sub>2</sub> &lt;2) or have specific contraindications (<strong>strong recommendation, high-quality evidence</strong>). Choice of anticoagulation therapy should be based on patient preferences and patient history. Options for anticoagulation therapy may include warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban. </p>
<p><strong><span style="text-decoration: underline;">Recommendation 5</span></strong></p>
<p>The AAFP strongly recommends against dual treatment with anticoagulant and antiplatelet therapy in most patients who have atrial fibrillation (<strong>strong recommendation, moderate-quality evidence</strong>).</p>
<p><strong><span style="text-decoration: underline;">Definitions</span></strong></p>
<p><strong>American Academy of Family Physicians Grading System</strong>&dagger;</p>
<table border="1" cellspacing="1" cellpadding="3" summary="Table: American Academy of Family Physicians Grading System">
    <thead>
        <tr>
            <th class="Center" valign="top" scope="col">Recommendation*</th>
            <th class="Center" valign="top" scope="col">Definition</th>
            <th class="Center" valign="top" scope="col">Quality of Evidence**</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td class="Center" valign="top" rowspan="2">Strong</td>
            <td valign="top" rowspan="2">High confidence in the net benefit for patient-oriented outcomes. Most informed patients would choose recommended option.</td>
            <td class="Center" valign="top">High</td>
        </tr>
        <tr>
            <td class="Center" valign="top">Moderate</td>
        </tr>
        <tr>
            <td class="Center" valign="top" rowspan="2">Weak</td>
            <td valign="top" rowspan="2">Lower confidence in the net benefit for patient-oriented outcomes. Patient choices may vary based on values and preferences.</td>
            <td class="Center" valign="top">Moderate</td>
        </tr>
        <tr>
            <td class="Center" valign="top">Low</td>
        </tr>
    </tbody>
</table>
<p class="Note">&dagger;The AAFP uses a modified version of Grading of Recommendations Assessment, Development and Evaluation (GRADE). <br />
*Recommendations can be either for or against an intervention or testing modality.<br />
**The strength of the recommendation should be consistent with the quality of the evidence such that strong recommendations are based on high-quality evidence, whereas weak recommendations are based on low- to moderate-quality evidence. Very low-quality evidence should be considered insufficient for a recommendation unless there are highly unusual circumstances and the benefits would greatly outweigh the harms.</p>
<p><strong>Good Practice Point</strong> &ndash; The GRADE system also provides opportunities to issue guideline recommendations without a rating when appropriate (e.g., those that will be helpful to a clinician but for which there is no direct evidence to support the recommendation). These statements are labeled by the AAFP as "good practice points."</p>
<p><strong>Quality of Evidence</strong></p>
<p><strong>High Quality</strong>: Further research is very unlikely to change confidence in the estimate of effect.<strong></strong></p>
<p><strong>Moderate Quality</strong>: Further research is likely to have an important impact on confidence in the estimate of effect, and may change the estimate. </p>
<p><strong>Low Quality</strong>: Further research is very likely to have an important impact on confidence in the estimate of effect, and is likely to change the estimate. </p>
<p><strong>Very Low Quality</strong>: Any estimate of effect is very uncertain.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Clinical Algorithm(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>None provided</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Scope
</h2>
<div class='field field_text'>
<h3>
Disease/Condition(s)
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Atrial fibrillation </li>
    <li>Stroke </li>
</ul>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Guideline Category
</h3>
<div class='FieldValue'>
Management
</div>
<div class='FieldValue'>
Prevention
</div>
<div class='FieldValue'>
Risk Assessment
</div>
<div class='FieldValue'>
Treatment
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Clinical Specialty
</h3>
<div class='FieldValue'>
Cardiology
</div>
<div class='FieldValue'>
Family Practice
</div>
<div class='FieldValue'>
Geriatrics
</div>
<div class='FieldValue'>
Internal Medicine
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Intended Users
</h3>
<div class='FieldValue'>
Advanced Practice Nurses
</div>
<div class='FieldValue'>
Physician Assistants
</div>
<div class='FieldValue'>
Physicians
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Objective(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>To provide recommendations for primary care-relevant pharmacologic treatments of patients who have nonvalvular atrial fibrillation </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Target Population
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Adults who have atrial fibrillation, as defined by electrocardiographic evidence of atrial fibrillation with or without symptoms </p>
<p class="Note"><strong>Note</strong>: All frequencies and durations of atrial fibrillation (paroxysmal, persistent, and permanent) are included. This guideline does not apply to patients who have atrial fibrillation due to a reversible cause (post-operative, post-myocardial infarction, or due to hyperthyroidism) or patients who have atrial fibrillation due to valvular disease.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Interventions and Practices Considered
</h3>
<div class='FieldValue'>
<ol style="list-style-type: decimal;" start="1">
    <li>Rate control therapy
    <ul style="list-style-type: disc;">
        <li>Beta-blockers </li>
        <li>Non-dihydropyridine calcium-channel blockers </li>
    </ul>
    </li>
    <li>Rhythm control therapy for certain patients based on patient symptoms, exercise tolerance, and patient preference </li>
    <li>Lenient versus strict rate control </li>
    <li>Discussing the risk of stroke and bleeding with all patients considering anticoagulation </li>
    <li>Using the continuous CHADS<sub>2</sub> (Congestive heart failure, Hypertension, Age 75+, Diabetes mellitus, prior Stroke, transient ischemic attack or thromboembolic event) or continuous CHA<sub>2</sub>DS<sub>2</sub>-VASc (Congestive heart failure, Hypertension, Age 75+, Diabetes mellitus, prior Stroke, transient ischemic attack or thromboembolic event, Vascular disease, Age 65-74, Sex category) for prediction of risk of stroke </li>
    <li>Using HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly [&gt;65 years], Drugs/alcohol concomitantly) for prediction of risk for bleeding </li>
    <li>Chronic anticoagulation therapy including warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban </li>
    <li>Dual treatment with anticoagulant and antiplatelet therapy (recommendation against) </li>
</ol>
</div>

</div>
<div class='field field_text'>
<h3>
Major Outcomes Considered
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Maintenance of ventricular rate and sinus rhythm </li>
    <li>Symptom relief </li>
    <li>Quality of life </li>
    <li>All-cause and cardiovascular mortality </li>
    <li>Stroke </li>
    <li>Systemic embolism </li>
    <li>Cardiovascular events </li>
    <li>Hospitalizations </li>
    <li>Major and minor bleeding </li>
    <li>Other adverse events due to medications </li>
</ul>
</div>

</div>

</div>
<div class='section'>
<h2>Methodology
</h2>
<div class='field field_picklist-many'>
<h3>
Methods Used to Collect/Select the Evidence
</h3>
<div class='FieldValue'>
Hand-searches of Published Literature (Primary Sources)
</div>
<div class='FieldValue'>
Hand-searches of Published Literature (Secondary Sources)
</div>
<div class='FieldValue'>
Searches of Electronic Databases
</div>
<div class='FieldValue'>
Searches of Unpublished Data
</div>

</div>
<div class='field field_text'>
<h3>
Description of Methods Used to Collect/Select the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong><span style="text-decoration: underline;">Systematic Reviews</span></strong></p>
<p>In 2013, the Agency for Healthcare Research and Quality (AHRQ) published two comparative effectiveness reviews. The first report, <em>Treatment of Atrial Fibrillation: Comparative Effectiveness Review No. 119</em>, reviewed the evidence for pharmacologic and surgical treatment of atrial fibrillation. The second review, <em>Stroke Prevention in Atrial Fibrillation: Comparative Effectiveness Review No. 123</em>, reviewed the evidence for different anticoagulation strategies for patients with atrial fibrillation. These reports were based on literature searches from January 1, 2000, to August 14, 2012. Refer to the systematic reviews (see the "Availability of Companion Documents" field) for search information and results.</p>
<p><strong><span style="text-decoration: underline;">Updated Literature Search</span></strong></p>
<p>A targeted, updated literature search using the same search criteria outlined in AHRQ reports was completed by the American Academy of Family Physicians (AAFP) medical librarian. The updated search resulted in 217 articles spanning the time from the completion of the AHRQ reports in 2012 through December 31, 2015. The search strategy is outlined in Appendix A of the original guideline document. Two reviewers independently examined citations and abstracts using the same inclusion and exclusion criteria that were used in the AHRQ evidence reports. A full text article was reviewed if at least one reviewer thought it should be included. This resulted in the review of 91 full text articles. Following exclusion of 48 articles, the remaining 43 articles underwent assessment for risk of bias and study quality. Each relevant study was rated for quality (good, fair, poor) by at least two independent reviewers using the approach outlined by the AHRQ <em>Methods Guide for Effectiveness and Comparative Effectiveness Reviews</em>. In keeping with the AHRQ methods, only studies that were rated as good or fair were included for consideration. Studies rated as poor were not included. For this updated evidence review, 16 articles were included (see Appendix B in the original guideline). The updated literature search resulted in the inclusion of one additional RCT with a new medication (edoxaban) that was not addressed in the AHRQ report on stroke prevention. This RCT was used to inform Recommendation 4 on options for chronic anticoagulation. The other studies found in the updated search were observational and secondary analyses of RCTs included in the AHRQ reports. These additional studies did not change the conclusions from the original AHRQ evidence reports. However, these analyses were considered by the panel in determining the recommendations and are discussed in the guideline text as appropriate.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Number of Source Documents
</h3>
<div class='FieldValue'>
<div class="content_para"><p>16 articles were included in the guideline text from the updated literature search.</p>
<p>Refer to the literature flow diagrams in the Agency for Healthcare Research and Quality (AHRQ) reports (see the "Availability of Companion Documents" field) for numbers of source documents.</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Methods Used to Assess the Quality and Strength of the Evidence
</h3>
<div class='FieldValue'>
Weighting According to a Rating Scheme (Scheme Given)
</div>

</div>
<div class='field field_text'>
<h3>
Rating Scheme for the Strength of the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong><span style="text-decoration: underline;">Quality of Evidence</span></strong></p>
<p><strong>High Quality</strong>: Further research is very unlikely to change confidence in the estimate of effect. </p>
<p><strong>Moderate Quality</strong>: Further research is likely to have an important impact on confidence in the estimate of effect, and may change the estimate. </p>
<p><strong>Low Quality</strong>: Further research is very likely to have an important impact on confidence in the estimate of effect, and is likely to change the estimate. </p>
<p><strong>Very Low Quality</strong>: Any estimate of effect is very uncertain.</p></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Methods Used to Analyze the Evidence
</h3>
<div class='FieldValue'>
Meta-Analysis
</div>
<div class='FieldValue'>
Review of Published Meta-Analyses
</div>
<div class='FieldValue'>
Systematic Review
</div>

</div>
<div class='field field_text'>
<h3>
Description of the Methods Used to Analyze the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The full Agency for Healthcare Research and Quality (AHRQ) evidence reports provide details on the data extraction, quality assessment of individual studies, data synthesis, strength of the body of evidence, and applicability across key questions for each systematic review. </p>
<p>The evidence from the systematic reviews was evaluated using a modified version of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to rate the quality of the evidence for each outcome and the overall strength of each recommendation (see the "Rating Scheme for the Strength of the Evidence" and the "Rating Scheme for the Strength of the Recommendations" fields). </p>
<p>Quantitative risk information was included in the supporting text using data from the AHRQ reports and individual studies, as appropriate. The number needed to treat/harm was calculated from these data. Evidence tables were created using the GRADEpro Guideline Development Tool (Software) (McMaster University, 2015 [developed by Evidence Prime, Inc.]). Available at <a href="https://gradepro.org/" title="GRADEpro Web site">gradepro.org</a>.</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Methods Used to Formulate the Recommendations
</h3>
<div class='FieldValue'>
Expert Consensus
</div>

</div>
<div class='field field_text'>
<h3>
Description of Methods Used to Formulate the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p><span style="text-decoration: underline;"><strong>Differences from Previous Guideline</strong></span></p>
<p>This guideline updates and replaces an earlier guideline published in 2003 from the American Academy of Family Physicians (AAFP) and the American College of Physicians, which was reaffirmed by the AAFP in 2008. The topic was nominated to the Agency of Healthcare Research and Quality (AHRQ) for an updated evidence review in 2011. Changes in the methodology and scope of the guideline include the following:</p>
<ul style="list-style-type: disc;">
    <li>Adding a consumer/patient representative </li>
    <li>Including evidence for new direct oral anticoagulants </li>
    <li>Including evidence on strict versus lenient rate control </li>
    <li>Narrowing the scope of the guideline to focus solely on pharmacologic management </li>
    <li>Adding a recommendation on risk assessment for stroke </li>
    <li>Adding shared decision-making tools to compare treatment options for rate control and anticoagulation </li>
</ul>
<p><span style="text-decoration: underline;"><strong>Systematic Review</strong></span></p>
<p>In 2013, AHRQ published two comparative effectiveness reviews. The first report, <em>Treatment of Atrial Fibrillation: Comparative Effectiveness Review No. 119</em>, reviewed the evidence for pharmacologic and surgical treatment of atrial fibrillation. The second review, <em>Stroke Prevention in Atrial Fibrillation: Comparative Effectiveness Review No. 123</em>, reviewed the evidence for different anticoagulation strategies for patients with atrial fibrillation. These reports were based on literature searches from January 1, 2000, to August 14, 2012.</p>
<p>The scope of the AHRQ reports was reviewed, and the panel chose to focus on the following key questions that they considered most relevant to primary care practice:</p>
<p><strong>Treatment of Atrial Fibrillation</strong></p>
<p><strong>Key question (KQ) 1</strong>: What are the comparative safety and effectiveness of pharmacological agents used for ventricular rate control in patients with atrial fibrillation? Do the comparative safety and effectiveness of these therapies differ among specific patient subgroups of interest?</p>
<p><strong>KQ2</strong>: What are the comparative safety and effectiveness of a strict rate-control strategy versus a more lenient rate-control strategy in patients with atrial fibrillation? Do the comparative safety and effectiveness of these therapies differ among specific patient subgroups of interest?</p>
<p><strong>KQ6</strong>: What are the comparative safety and effectiveness of rate-control therapies compared with rhythm-control therapies in patients with atrial fibrillation? Do the comparative safety and effectiveness of these therapies differ among specific patient subgroups of interest?</p>
<p><strong>Stroke Prevention in Atrial Fibrillation</strong></p>
<p><strong>KQ1</strong>: In patients with nonvalvular atrial fibrillation, what are the comparative diagnostic accuracy and impact on clinical decision making (diagnostic thinking, therapeutic, and patient outcome efficacy) of available clinical and imaging tools for predicting thromboembolic risk?</p>
<p><strong>KQ2</strong>: In patients with nonvalvular atrial fibrillation, what are the comparative diagnostic accuracy and impact on clinical decision making (diagnostic thinking, therapeutic, and patient outcome efficacy) of clinical tools and associated risk factors for predicting bleeding events?</p>
<p><strong>KQ3</strong>: What are the comparative safety and effectiveness of specific anticoagulation therapies, antiplatelet therapies, and procedural interventions for preventing thromboembolic events:</p>
<ol style="list-style-type: lower-alpha;" start="a">
    <li>In patients with nonvalvular atrial fibrillation? </li>
    <li>In specific subpopulations of patients with nonvalvular fibrillation? </li>
</ol>
<p>The sections of the AHRQ evidence reports relevant to these key questions were reviewed and used as the foundation for the AAFP's recommendations.</p>
<p><span style="text-decoration: underline;"><strong>Constructing the Guideline</strong></span></p>
<p>The AAFP's Commission on Health of the Public and Science appointed a guideline development group (GDG) to update the guideline. Specifics on the guideline development panel and process can be found in the <em>AAFP Clinical Practice Guideline Manual</em> (see the "Availability of Companion Documents" field). The GDG reviewed the 2003 guideline and the two AHRQ evidence reports. The panel evaluated each recommendation from the guideline and determined those that would be included in the update. The GDG determined that the recommendations for pharmacologic treatment of atrial fibrillation and anticoagulation were the most relevant for family physicians.</p>
<p>The evidence from the systematic reviews was evaluated using a modified version of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to rate the quality of the evidence for each outcome and the overall strength of each recommendation. GRADE uses the term "strength of recommendation" to rate the extent to which one can be confident that the desirable effects of an intervention outweigh the undesirable effects and reflect the degree to which there is evidence of improved patient-oriented health outcomes (see the "Rating Scheme for the Strength of the Recommendations" field). The GRADE system also provides opportunities to issue guideline recommendations without a rating when appropriate (e.g., those that will be helpful to a clinician but for which there is no direct evidence to support the recommendation). These statements are labeled by the AAFP as "good practice points."</p>
<p>Guideline recommendations were finalized based on consensus of the GDG. Patient-oriented outcomes were prioritized in the guideline recommendations. Outcomes assessed included maintenance of ventricular rate and sinus rhythm; symptom relief; quality of life; all-cause and cardiovascular mortality; stroke; systemic embolism; cardiovascular events; hospitalizations; major and minor bleeding; and other adverse events due to medications. The recommendations were worded to reflect the strength and direction of the recommendation, and the quality of the evidence was listed parenthetically.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rating Scheme for the Strength of the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong><span style="text-decoration: underline;">American Academy of Family Physicians Grading System</span></strong>&dagger;</p>
<table border="1" cellspacing="1" cellpadding="3" summary="Table: American Academy of Family Physicians Grading System">
    <thead>
        <tr>
            <th class="Center" valign="top" scope="col">Recommendation*</th>
            <th class="Center" valign="top" scope="col">Definition</th>
            <th class="Center" valign="top" scope="col">Quality of Evidence**</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td class="Center" valign="top" rowspan="2">Strong</td>
            <td valign="top" rowspan="2">High confidence in the net benefit for patient-oriented outcomes. Most informed patients would choose recommended option.</td>
            <td class="Center" valign="top">High</td>
        </tr>
        <tr>
            <td class="Center" valign="top">Moderate</td>
        </tr>
        <tr>
            <td class="Center" valign="top" rowspan="2">Weak</td>
            <td valign="top" rowspan="2">Lower confidence in the net benefit for patient-oriented outcomes. Patient choices may vary based on values and preferences.</td>
            <td class="Center" valign="top">Moderate</td>
        </tr>
        <tr>
            <td class="Center" valign="top">Low</td>
        </tr>
    </tbody>
</table>
<p class="Note">&dagger;The AAFP uses a modified version of Grading of Recommendations Assessment, Development and Evaluation (GRADE). <br />
*Recommendations can be either for or against an intervention or testing modality.<br />
**The strength of the recommendation should be consistent with the quality of the evidence such that strong recommendations are based on high-quality evidence, whereas weak recommendations are based on low- to moderate-quality evidence. Very low-quality evidence should be considered insufficient for a recommendation unless there are highly unusual circumstances and the benefits would greatly outweigh the harms.</p>
<p><strong>Good Practice Point</strong> &ndash; The GRADE system also provides opportunities to issue guideline recommendations without a rating when appropriate (e.g., those that will be helpful to a clinician but for which there is no direct evidence to support the recommendation). These statements are labeled by the AAFP as "good practice points."</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Cost Analysis
</h3>
<div class='FieldValue'>
<div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Method of Guideline Validation
</h3>
<div class='FieldValue'>
External Peer Review
</div>
<div class='FieldValue'>
Internal Peer Review
</div>

</div>
<div class='field field_text'>
<h3>
Description of Method of Guideline Validation
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong><span style="text-decoration: underline;">Peer Review</span></strong></p>
<p>The guideline was peer-reviewed by relevant external stakeholders. All comments and any modifications based on those comments were documented. The American Academy of Family Physicians (AAFP) Commission on Health of the Public and Science (CHPS) and Board of Directors reviewed and approved the final guideline in April of 2017. </p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Recommendations
</h2>
<div class='field field_text'>
<h3>
Type of Evidence Supporting the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The type of evidence supporting the recommendations is identified and graded for each recommendation (see the "Major Recommendations" field).</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Benefits/Harms of Implementing the Guideline Recommendations
</h2>
<div class='field field_text'>
<h3>
Potential Benefits
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Atrial fibrillation (AF) is a significant independent risk factor for stroke, causing 15% to 20% of ischemic strokes. Prophylactic treatment with anticoagulants has proven to be highly effective for the prevention of stroke in patients with AF. Vitamin K antagonists have been used successfully for more than 50 years and are considered to be the gold standard for anticoagulant therapy. Direct anticoagulants provide additional options for stroke prophylaxis in patients with AF. The risks, benefits, and burdens related to cost and quality of life are outlined in Table 5 of the original guideline document. Patients with multiple comorbidities&mdash;including diabetes mellitus, hypertension, heart failure, coronary artery disease, renal impairment, and cerebrovascular disease&mdash;were included in the studies. There is insufficient evidence to assess these subpopulations to determine their individual benefit from anticoagulation. Dose modifications may be required for patients with renal insufficiency, depending on the degree of renal impairment.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Potential Harms
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Prior to initiating treatment, clinicians should discuss the benefits and harms of the different anticoagulants, including potential medication cost and lifestyle modifications. Risk of bleeding should also be discussed. Careful risk assessment is essential, as patients with a low risk of stroke may not be appropriate for anticoagulation. Due to the increased risk of bleeding, dual therapy with aspirin and anticoagulants should be avoided.</p>
<p>See Table 5 in the original guideline for risks of oral anticoagulants for stroke prevention in patients with atrial fibrillation. See Table 6 in the original guideline for risks of dual therapy.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Contraindications
</h2>
<div class='field field_text'>
<h3>
Contraindications
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Contraindications for warfarin include the following:</p>
<ul style="list-style-type: disc;">
    <li>Pregnancy, except in women with mechanical heart valves </li>
    <li>Hemorrhagic tendencies or blood dyscrasias </li>
    <li>Recent or planned surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces </li>
    <li>Potential high levels of noncompliance in unsupervised patients </li>
    <li>Hypersensitivity to warfarin </li>
    <li>Malignant hypertension </li>
</ul>
<p>See Table 5 in the original guideline for additional risks and contraindications of oral anticoagulants for stroke prevention in patients with atrial fibrillation.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Qualifying Statements
</h2>
<div class='field field_text'>
<h3>
Qualifying Statements
</h3>
<div class='FieldValue'>
<div class="content_para"><p>These recommendations are provided only as assistance for clinicians making clinical decisions regarding the care of their patients. As such, they cannot substitute for the individual judgment brought to each clinical situation by the patient's family physician. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the clear understanding that continued research may result in new knowledge and recommendations. All American Academy of Family Physicians (AAFP) guidelines are scheduled for a review five years after completion or sooner if new evidence becomes available.</p>
<p>This guideline was developed using available evidence; however, gaps were identified. New research into these areas may affect the recommendations, at which time the guideline will be updated accordingly. Research gaps that would provide important information are provided in the original guideline document. </p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Implementation of the Guideline
</h2>
<div class='field field_text'>
<h3>
Description of Implementation Strategy
</h3>
<div class='FieldValue'>
<div class="content_para"><p>An implementation strategy was not provided.</p></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Implementation Tools
</h3>
<div class='FieldValue'>
Patient Resources
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Healthcare Quality Report Categories
</h2>
<div class='field field_picklist-many'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Living with Illness
</div>
<div class='FieldValue'>
Staying Healthy
</div>

</div>
<div class='field field_picklist-many'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>
<div class='FieldValue'>
Patient-centeredness
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information and Availability
</h2>
<div class='field field_citation'>
<h3>
Bibliographic Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>American Academy of Family Physicians. Updated clinical practice guideline: pharmacologic management of newly detected atrial fibrillation. Leawood (KS): American Academy of Family Physicians; 2017 Apr. 19 p.  [33 references]</td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date Released
</h3>
<div class='FieldValue'>
2017 Apr
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Guideline Developer(s)
</h3>
<div class='FieldValue'>
American Academy of Family Physicians - Medical Specialty Society
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Developer Comment
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not applicable</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Source(s) of Funding
</h3>
<div class='FieldValue'>
<div class="content_para"><p>All costs associated with the development of this guideline came exclusively from the operating budget of the American Academy of Family Physicians (AAFP).</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Committee
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Guideline Development Group</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of Group That Authored the Guideline
</h3>
<div class='FieldValue'>
<div class="content_para"><p><em>Guideline Development Group Members</em>: Jennifer L. Frost, MD, FAAFP (<em>writer, methodologist</em>), American Academy of Family Physicians, Leawood, KS; Doug Campos-Outcalt, MD, MPA (<em>writer</em>), Mercy Care Plan, Phoenix, AZ; David Hoelting, MD (<em>writer</em>), Pender-Mercy Medical Center, Pender, NE; Michael LeFevre, MD, MSPH (<em>writer, chair</em>), Department of Family and Community Medicine, University of Missouri, Columbia, MO; Kenneth W. Lin, MD, MPH, FAAFP (<em>writer</em>), Department of Family Medicine, Georgetown University, Washington, DC; William Vaughan (<em>writer, patient/consumer advocate</em>), Consumers United for Evidence-Based Healthcare, Baltimore, MD; Melanie D. Bird, PhD (<em>writer</em>, <em>AAFP staff liaison</em>), American Academy of Family Physicians, Leawood, KS</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Conflicts of interest (COI) were solicited in writing at the beginning of the guideline process and updated verbally at each subsequent call. No panel member disclosed any COI.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Snow V, Weiss KB, LeFevre M, McNamara R, Bass E, Green LA, Michl K, Owens DK, Susman J, Allen DI, Mottur-Pilson C. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2003 Dec 16;139(12):1009-17. [57 references] </p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Available from the <a href="http://www.aafp.org/dam/AAFP/documents/patient_care/clinical_recommendations/a-fib-guideline.pdf" title="American Academy of Family Physicians (AAFP) Web site">American Academy of Family Physicians (AAFP) Web site</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Availability of Companion Documents
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The following are available:</p>
<ul style="list-style-type: disc;">
    <li>Lopes RD, Crowley MJ, Shah BR, Melloni C, Wood KA, Chatterjee R, Povsic TJ, Dupre ME, Kong DF, Barros e Silva PGM, Santos MHH, Armaganijan LV, Katz M, Kosinski A, McBroom AJ, Chobot MM, Gray R, Sanders GD. Stroke prevention in atrial fibrillation. Comparative effectiveness review no. 123. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No. 13-EHC113-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2013 Aug. 341 p. Available from the <a href="https://www.effectivehealthcare.ahrq.gov/ehc/products/352/1668/stroke-atrial-fibrillation-report-130821.pdf" title="Agency for Healthcare Research and Quality (AHRQ) Web site" target="_blank">Agency for Healthcare Research and Quality (AHRQ) Web site</a>. </li>
    <li>Al-Khatib SM, Allen Lapointe N, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah BR, Kosinski A, McBroom AJ, Chobot MM, Gray R, Sanders GD. Treatment of atrial fibrillation. Comparative effectiveness review 119. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No.13-EHC095-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2013 Jun. 348 p. Available from the <a href="https://www.effectivehealthcare.ahrq.gov/ehc/products/358/1559/atrial-fibrillation-report-130628.pdf" title="AHRQ Web site" target="_blank">AHRQ Web site</a>. </li>
    <li>American Academy of Family Physicians. Clinical practice guideline manual. Leawood (KS): American Academy of Family Physicians; 2017. Available from the <a href="http://www.aafp.org/patient-care/clinical-recommendations/cpg-manual.html" title="American Academy of Family Physicians (AAFP) Web site">American Academy of Family Physicians (AAFP) Web site</a>. </li>
    <li>American Academy of Family Physicians. Developing clinical practice guidelines. Webcast series. Leawood (KS): American Academy of Family Physicians; 2017. Available from the <a href="http://www.aafp.org/patient-care/clinical-recommendations/practice-guidelines.html" title="AAFP Web site">AAFP Web site</a>. </li>
</ul></div>
</div>

</div>
<div class='field field_text'>
<h3>
Patient Resources
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The following is available:</p>
<ul style="list-style-type: disc;">
    <li>Arrhythmia. Patient information. Leawood (KS): American Academy of Family Physicians; 2017 Jun. 4 p. Available from the <a href="https://familydoctor.org/condition/arrhythmia/" title="FamilyDoctor.org Web site">FamilyDoctor.org Web site</a>. </li>
</ul>
<p class="Disclaimer">Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NGC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NGC summary was completed by ECRI on May 20, 2004. The information was verified by the guideline developer on June 4, 2004. This summary was updated by ECRI on March 6, 2007 following the U.S. Food and Drug Administration (FDA) advisory on Coumadin (warfarin sodium). This summary was updated by ECRI Institute on September 7, 2007 following the revised U.S. Food and Drug Administration (FDA) advisory on Coumadin (warfarin). This summary was updated by ECRI Institute on July 17, 2017. The updated information was verified by the guideline developer on August 10, 2017.</p>
<p>This NEATS assessment was completed by ECRI Institute on July 19, 2017. The information was verified by the guideline developer on August 10, 2017.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NGC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>
</div>

</div>

</div>
</body></html>